



## **Collegium to Present at the H.C. Wainwright Global Life Sciences Conference**

April 4, 2018

CANTON, Mass., April 04, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 10, 2018 at 11:55 a.m. CET at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.

### **About Collegium Pharmaceutical, Inc.**

Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.

### **About Xtampza ER**

Xtampza® ER is Collegium's first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Contact:

Alex Dasalla

[adasalla@collegiumpharma.com](mailto:adasalla@collegiumpharma.com)



Source: Collegium Pharmaceutical, Inc.